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Letters to the EditorTransarterial therapies for hepatocellular carcinoma (HCC):
A long way towards standardizationthe embolizing agent and its size could potentially make a differ-
ence. In the interim, reporting of actual and not projected data of
survival is cardinal for balanced conclusions and information
given to health providers and patients.
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We read with interest the articles by Burrel [1] and Park [2] on
transarterial chemoembolization (TACE) in HCC. They demon-
strate the lack of standardization of this technique, which has
led others to question its overall efﬁcacy [3], but also provide
the basis for important clariﬁcations.
Burrel et al. [1] used the newer DEB-BEADs, at a size of 300–
700 lm, to ensure controlled delivery of chemotherapy to the
tumor cells over a period of several days. DEB-BEADs decrease
the rate of chemotherapy-induced side effects but do not improve
survival [4]. They used a highly selected cohort of patients, 40% of
whom were staged as BCLC-A and they concluded that median
survival was 48.6 months after a median follow-up of 24.5
months. This indeed is a mathematical paradox, as actual follow-
up was much less than supposed survival; at the time of the
projected median survival, less than 15 patients were still at risk
of death according to the Kaplan–Meier curve and 35 had died,
i.e., there was no adequate follow-up for at least 50% of the cohort
and indeed 54/69 patients still alive did not have the median
survival follow-up. Therefore, their statement and conclusion
need to be revisited as they are based on projected and not actual
data, in a highly selected group of patients. Furthermore, the size
of the embolizing agent may not be optimal, as it does not allow
super-selective occlusion of smaller tumor feeding arteries.
For instance, polyvinyl alcohol particles can be as small as
45–150 lm [5].
The study by Park et al. [2] is a more pragmatic one, including
patients with more advanced disease and a few with BCLC-C
stage who would not be normally suitable for TACE [6]. Unfortu-
nately, the suboptimal gelfoam was used as the embolizing agent
and therefore the maximal therapeutic effect was probably not
reached. As we had previously pointed out, gelfoam only tempo-
rarily occludes the tumor vessels and the effect does not seem to
last for more than 14 days [7]. This important detail, among
others, was not taken into account in the recent Cochrane
meta-analysis [3].
Despite important advances in the ﬁeld, transarterial thera-
pies in HCC still suffer from a lack of standardization in the selec-
tion of patients, the embolizing agent used, the size of the
embolizing particles, the choice of the chemotherapeutic agent,
the interval between therapeutic sessions and agreement on
stopping rules [7]. Even the addition of chemotherapy has not
been proven to be superior to embolization alone in randomized
controlled trials [8]. Ideally, embolization should be done with
small and permanently occluding particles, to ensure more
selective occlusion of small feeding tumour arteries and fewer
side effects. This is an advantage of PVA particles, whose size is
smaller than that of DEB-BEADS.
Clearly randomized controlled trials are needed in order to
establish the optimal transarterial technique, as the choice of2013 vol. 58 j 194–198
